Skip to main content Skip to section navigation Skip to footer
Top
Lantern Pharma Inc.
INVESTORS
Home
Investors
Contact
About
Welcome
Mission
Partnering
Patents
A.I. Platform
Our Technology
RADR®
Collaborations
Pipeline
Overview
LP100 | LP184 | LP284 | LP300 | ADC Program
Clinical Trials
Compassionate Use
Publications
Posters
TEAM
Leadership
Board of Directors
Advisors
Lantern Careers
MEDIA
News
Press
Social Media
Newsletter
Videos
Webinars
ContactInvestors

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Media Coverage
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Media Coverage
  • Email Alerts
Dec 17, 2020 7:00am EST

Lantern Pharma Announces Collaboration with World Leading Brain Cancer Program at Johns Hopkins to Further Develop LP-184 as Therapy for Glioblastoma

Dec 15, 2020 7:00am EST

Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Barrier Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers

Nov 24, 2020 7:30am EST

Lantern Pharma Announces Upcoming Conference Presentations

Oct 29, 2020 3:59pm EDT

Lantern Pharma Reports Third Quarter 2020 Financial Results & Continued Operational Progress

Oct 22, 2020 7:00am EDT

Lantern Pharma to Host Third Quarter 2020 Operating and Financial Results Conference Call on October 29, 2020 at 4:00 p.m. ET

Oct 05, 2020 7:46am EDT

Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184, a Next-Generation, Targeted DNA-Damaging Agent

Sep 22, 2020 7:55am EDT

Lantern Pharma Announces Collaboration and Research Agreement with Fox Chase Cancer Center Focused on Advancing the Development of LP-184 in Pancreatic Cancer

Aug 27, 2020 7:55am EDT

Lantern Pharma Announces Upcoming Conference Presentations

Aug 14, 2020 2:25pm EDT

Lantern Pharma Interview to Air on Bloomberg International on the RedChip Money Report

Jul 30, 2020 6:57am EDT

Lantern Pharma Reports Second Quarter 2020 Financial Results and Continued Corporate Progress

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed

Join our Mailing List to get the latest Lantern news, sent right to your inbox

Sign me up for:

This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.
Never spam. Unsubscribe anytime.
Tweets by LanternPharma
View on Webflow
About
Welcome
Mission
Partnering
Patents
A.I. Platform
Our Technology
RADR®
Collaborations
Pipeline
Overview
LP100 | LP184 | LP284 | LP300 | ADC Program
Clinical Trials
Compassionate Use
Publications
Posters
TEAM
Leadership
Board Of Directors
Advisors
Lantern Careers
MEDIA
News
Press
Social Media
Newsletter
Videos
Webinars
Investors
Contact
TwitterYoutubeLinkedin
©Copyright 2023 Lantern Pharma Inc.
Privacy Policy